Skip to content

Study · Randomized controlled trial · 2007

3 results

Estimation of the size and shape of GH secretory bursts in healthy women using a physiological estradiol clamp and variable-waveform deconvolution model.

Veldhuis JD, Keenan DM, Bowers CY

American journal of physiology. Regulatory, integrative and comparative physiology30 May 2007Cited by 7 (Europe PMC)

PMID17537842 (opens in a new tab)DOI10.1152/ajpregu.00159.2007 (opens in a new tab)PepBankPUB-17537842
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy women under an estradiol clamp, burstlike GH secretion after bolus GHRP‑2 in postmenopausal women was 29% of that in premenopausal women.

    In plain wordsIn healthy women, growth hormone bursts after a GHRP‑2 shot were much smaller after menopause than before.

    Peptide
    GHRP-2
    Outcome
    DecreaseBurstlike GH secretion after bolus GHRP-2, postmenopausal versus premenopausal
    Study

    n: not reported in source

    Comparator
    Premenopausal women
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    GH burst secretion, POST relative to PRE
    29%
    bolus GHRP-2

    Source sentences

    Summary
    markedly attenuated burstlike GH secretion in response to bolus GHRP-2 (29%), bolus GHRH (30%), l-arginine (37%), constant GHRP-2 (38%), and constant GHRH (42%)
    1 context sentence
    Summary · context
    2) stimulation of fasting GH secretion by each of GHRH, GHRP-2 (a ghrelin analog), and l-arginine (to putatively limit SSergic restraint)
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy women under an estradiol clamp, burstlike GH secretion after constant GHRP‑2 in postmenopausal women was 38% of that in premenopausal women.

    In plain wordsIn healthy women, growth hormone bursts during a steady GHRP‑2 infusion were much smaller after menopause than before.

    Peptide
    GHRP-2
    Outcome
    DecreaseBurstlike GH secretion after constant GHRP-2, postmenopausal versus premenopausal
    Study

    n: not reported in source

    Comparator
    Premenopausal women
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    GH burst secretion, POST relative to PRE
    38%
    constant GHRP-2

    Source sentences

    Summary
    markedly attenuated burstlike GH secretion in response to bolus GHRP-2 (29%), bolus GHRH (30%), l-arginine (37%), constant GHRP-2 (38%), and constant GHRH (42%)
    1 context sentence
    Summary · context
    2) stimulation of fasting GH secretion by each of GHRH, GHRP-2 (a ghrelin analog), and l-arginine (to putatively limit SSergic restraint)
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy women under an estradiol clamp, the time to maximal GH secretion after bolus GHRP‑2 was 32% shorter in postmenopausal than in premenopausal women.

    In plain wordsIn healthy women, growth hormone peaked sooner after a GHRP‑2 shot after menopause than before.

    Peptide
    GHRP-2
    Outcome
    DecreaseTime to maximal GH secretion after bolus GHRP-2, postmenopausal versus premenopausal
    Study

    n: not reported in source

    Comparator
    Premenopausal women
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Time to maximal GH secretion, POST versus PRE
    −32%
    bolus GHRP-2

    Source sentences

    Summary
    a 160% prolongation and 32% abbreviation of the time required to achieve maximal GH secretion after injection of l-arginine and bolus GHRP-2, respectively
    1 context sentence
    Summary · context
    2) stimulation of fasting GH secretion by each of GHRH, GHRP-2 (a ghrelin analog), and l-arginine (to putatively limit SSergic restraint)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.